Scynexis Inc balance sheet
At the end of fiscal 2025, Scynexis Inc had total assets of $59.0m, total liabilities of $9.7m and shareholders' equity of $49.4m. It held $21.3m in cash against $0 of debt: net cash of $21.3m.
Balance sheet
| Fiscal year | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1 | 32 | 47 | 36 | 11 | 11 | 42 | 93 | 104 | 46 | 34 | 16 | 21 | 10 |
| Receivables | 1 | 1 | — | — | — | — | — | 0 | 1 | 2 | 0 | — | — | — |
| Inventory | — | — | — | — | — | — | — | 0 | 0 | 1 | 0 | — | — | — |
| Total current assets | 3 | 40 | 48 | 59 | 45 | 51 | 52 | 98 | 109 | 79 | 102 | 72 | 40 | 56 |
| Total assets | 12 | 40 | 49 | 60 | 46 | 53 | 57 | 103 | 120 | 88 | 128 | 91 | 59 | 75 |
| Accounts payable | 2 | 0 | 1 | 2 | 4 | 4 | 7 | 5 | 8 | 6 | 7 | 5 | 2 | 3 |
| Deferred revenue (current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 | 1 | 2 | 0 | 0 |
| Total current liabilities | 18 | 5 | 7 | 4 | 10 | 6 | 11 | 26 | 14 | 18 | 16 | 24 | 6 | 6 |
| Short-term debt | 15 | 0 | — | 0 | 4 | 0 | — | — | 0 | — | — | — | — | — |
| Long-term debt | — | — | 0 | 14 | 10 | 15 | 0 | — | 34 | — | — | — | — | — |
| Total debt | 15 | 0 | 0 | 14 | 15 | 15 | 0 | 0 | 35 | 35 | — | 0 | 0 | 0 |
| Total liabilities | 33 | 6 | 7 | 25 | 24 | 22 | 44 | 80 | 79 | 85 | 55 | 36 | 10 | 8 |
| Shareholders' equity | −108 | 33 | 42 | 35 | 21 | 31 | 13 | 23 | 41 | 3 | 73 | 55 | 49 | 67 |
| Non-controlling interests and other (assets − liabilities − equity) | 87 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net debt (negative = net cash) | 14 | −32 | −47 | −21 | 3 | 4 | −42 | −93 | −69 | −11 | −34 | −16 | −21 | −10 |
| Shares outstanding | — | — | — | — | — | — | 10m | — | 29m | — | — | — | 54m | 10m |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 80 | 72 | 52 | 56 | 49 | 40 | 63 | 56 |
| Total assets | 99 | 91 | 68 | 61 | 51 | 59 | 78 | 75 |
| Accounts payable | 5 | 5 | 4 | 6 | 3 | 2 | 6 | 3 |
| Deferred revenue (current) | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 |
| Total current liabilities | 26 | 24 | 9 | 11 | 8 | 6 | 16 | 6 |
| Total liabilities | 41 | 36 | 17 | 16 | 15 | 10 | 36 | 8 |
| Shareholders' equity | 59 | 55 | 51 | 44 | 36 | 49 | 41 | 67 |
| Shares outstanding | 38m | 38m | 39m | 39m | 42m | 5m | 62m | 10m |
Compare with peers
- Celularity Inc balance sheet
- Cytomx Therapeutics, Inc. balance sheet
- Proqr Therapeutics N.V. balance sheet
- Janux Therapeutics, Inc. balance sheet
- Keros Therapeutics, Inc. balance sheet
Head to head: CELU vs SCYXCTMX vs SCYXPRQR vs SCYX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies